About Ergomed (LON:ERGO)
Ergomed plc is a provider of drug development services to the pharmaceutical industry. The Company operates through two segments: clinical research services (CRS), and drug safety and medical information services (DS&MI). It provides a range of clinical trial planning, management and monitoring services. It is focused on oncology, neurology and immunology, and the development of orphan drugs. It has two businesses: Services Business and Co-Development Business. The Services Business is a clinical research business providing services to the pharmaceutical and biotechnology industry. The Co-Development Business is a portfolio of partnerships with pharmaceutical and biotechnology companies, providing its drug development services in exchange for a carried interest in any revenues attributable to the drug asset, including out licensing milestones, as well as sales of the product. It provides clinical development, trial management and pharmacovigilance services to over 100 clients.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Trailing EPSGBX 0.01
Return on Equity2.69%
Return on Assets1.73%
Ergomed (LON:ERGO) Frequently Asked Questions
What is Ergomed's stock symbol?
Ergomed trades on the London Stock Exchange (LON) under the ticker symbol "ERGO."
How were Ergomed's earnings last quarter?
Ergomed PLC (LON:ERGO) issued its quarterly earnings results on Monday, September, 18th. The company reported $1.20 earnings per share for the quarter. The company earned $22.91 million during the quarter. Ergomed had a net margin of 2.07% and a return on equity of 2.69%. View Ergomed's Earnings History.
Where is Ergomed's stock going? Where will Ergomed's stock price be in 2017?
3 Wall Street analysts have issued twelve-month target prices for Ergomed's stock. Their forecasts range from GBX 300 to GBX 360. On average, they expect Ergomed's stock price to reach GBX 321.33 in the next twelve months. View Analyst Ratings for Ergomed.
Who are some of Ergomed's key competitors?
Some companies that are related to Ergomed include Viking Therapeutics (VKTX), Aldeyra Therapeutics (ALDX), Summit Therapeutics (SUMM), Conatus Pharmaceuticals (CNAT), Axsome Therapeutics (AXSM), Bellerophon Therapeutics (BLPH), Zafgen (ZFGN), AcelRx Pharmaceuticals (ACRX), Ophthotech (OPHT), Ampio Pharmaceuticals (AMPE), Galmed Pharmaceuticals (GLMD), Redhill Biopharma (RDHL), Verona Pharma (VRP), ProQR Therapeutics (PRQR), Shield Therapeutics (STX), Trevena (TRVN), Opexa Therapeutics (ACER) and Aptevo Therapeutics (APVO).
Who are Ergomed's key executives?
Ergomed's management team includes the folowing people:
- Dan Weng, Chief Executive Officer, Director
- Miroslav Reljanovic, Executive Vice Chairman of the Board
- Stephen A. Stamp, Chief Financial Officer, Director (Age 54)
- Jan Petracek, Chief Executive Officer of PrimeVigilance
- Andrew Mackie, Chief Business Officer, Executive Director (Age 50)
- Danko Dominis, Ergomed Head of Business Development
- Branka Duvnjak, Ergomed Head of Site Management
- Terry L. Murdock, President of North America, Executive Director of Global Clinical Operations (Age 49)
- Chris Wilson, Head of Quality and Regulatory
- Peter Lutz George, Non-Executive Chairman of the Board
How do I buy Ergomed stock?
Shares of Ergomed and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Ergomed's stock price today?
One share of Ergomed stock can currently be purchased for approximately GBX 182.50.
How big of a company is Ergomed?
Ergomed has a market capitalization of £68.81 million.
How can I contact Ergomed?
Ergomed's mailing address is 26-24 Frederick Sanger Road, GUILDFORD, GU2 7YD, United Kingdom. The company can be reached via phone at +44-1483-503205.
MarketBeat Community Rating for Ergomed (ERGO)MarketBeat's community ratings are surveys of what our community members think about Ergomed and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Ergomed (LON:ERGO) Earnings History and Estimates Chart
Ergomed (LON ERGO) Earnings History by Quarter
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|9/18/2017||S1 2017||GBX 1.20||GBX 2,291 million||View||N/A|
Ergomed (LON:ERGO) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Ergomed (LON:ERGO)
No dividend announcements for this company have been tracked by MarketBeat.com
Ergomed (LON ERGO) Insider Trading and Institutional Ownership History
Ergomed (LON ERGO) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|4/3/2017||Peter George||Insider||Buy||100,000||GBX 190||£190,000|
Ergomed (LON ERGO) News Headlines
Ergomed (LON:ERGO) SEC Filings
Financials are not available for this stock.
Ergomed (LON ERGO) Stock Chart for Monday, December, 11, 2017